Connection

SHUXING ZHANG to Humans

This is a "connection" page, showing publications SHUXING ZHANG has written about Humans.
Connection Strength

0.131
  1. Editorial: The Elephant in the Room: Targeting Ras for Therapeutic Development. Mini Rev Med Chem. 2016; 16(5):343-4.
    View in: PubMed
    Score: 0.010
  2. Polypharmacology: drug discovery for the future. Expert Rev Clin Pharmacol. 2013 Jan; 6(1):41-7.
    View in: PubMed
    Score: 0.008
  3. A novel multi-modal drug repurposing approach for identification of potent ACK1 inhibitors. Pac Symp Biocomput. 2013; 29-40.
    View in: PubMed
    Score: 0.008
  4. Quantitative prediction of glucuronidation in humans using the in vitro- in vivo extrapolation approach. Curr Top Med Chem. 2013; 13(11):1343-52.
    View in: PubMed
    Score: 0.008
  5. Novel insights of structure-based modeling for RNA-targeted drug discovery. J Chem Inf Model. 2012 Oct 22; 52(10):2741-53.
    View in: PubMed
    Score: 0.008
  6. In silico lead identification and optimization for drug discovery. Curr Pharm Des. 2012; 18(9):1171-2.
    View in: PubMed
    Score: 0.008
  7. From laptop to benchtop to bedside: structure-based drug design on protein targets. Curr Pharm Des. 2012; 18(9):1217-39.
    View in: PubMed
    Score: 0.008
  8. Computational prediction of protein hot spot residues. Curr Pharm Des. 2012; 18(9):1255-65.
    View in: PubMed
    Score: 0.008
  9. A critical assessment of combined ligand- and structure-based approaches to HERG channel blocker modeling. J Chem Inf Model. 2011 Nov 28; 51(11):2948-60.
    View in: PubMed
    Score: 0.008
  10. Recent development of anticancer therapeutics targeting Akt. Recent Pat Anticancer Drug Discov. 2011 Jan; 6(1):146-59.
    View in: PubMed
    Score: 0.007
  11. Targeting microRNAs with small molecules: from dream to reality. Clin Pharmacol Ther. 2010 Jun; 87(6):754-8.
    View in: PubMed
    Score: 0.007
  12. Molecular networks in drug discovery. Crit Rev Biomed Eng. 2010; 38(2):143-56.
    View in: PubMed
    Score: 0.007
  13. Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain. Bioorg Med Chem. 2009 Oct 01; 17(19):6983-92.
    View in: PubMed
    Score: 0.007
  14. Small molecule compounds targeting miRNAs for cancer therapy. Adv Drug Deliv Rev. 2015 Jan; 81:104-16.
    View in: PubMed
    Score: 0.002
  15. Genetic and pharmacological strategies to refunctionalize the von Hippel Lindau R167Q mutant protein. Cancer Res. 2014 Jun 01; 74(11):3127-36.
    View in: PubMed
    Score: 0.002
  16. Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell. 2013 Aug 01; 154(3):556-68.
    View in: PubMed
    Score: 0.002
  17. Transcription factors ETS2 and MESP1 transdifferentiate human dermal fibroblasts into cardiac progenitors. Proc Natl Acad Sci U S A. 2012 Aug 07; 109(32):13016-21.
    View in: PubMed
    Score: 0.002
  18. Accurate prediction of glucuronidation of structurally diverse phenolics by human UGT1A9 using combined experimental and in silico approaches. Pharm Res. 2012 Jun; 29(6):1544-61.
    View in: PubMed
    Score: 0.002
  19. SULT1A3-mediated regiospecific 7-O-sulfation of flavonoids in Caco-2 cells can be explained by the relevant molecular docking studies. Mol Pharm. 2012 Apr 02; 9(4):862-73.
    View in: PubMed
    Score: 0.002
  20. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst. 2012 Feb 08; 104(3):228-39.
    View in: PubMed
    Score: 0.002
  21. 3-Formylchromone interacts with cysteine 38 in p65 protein and with cysteine 179 in I?Ba kinase, leading to down-regulation of nuclear factor-?B (NF-?B)-regulated gene products and sensitization of tumor cells. J Biol Chem. 2012 Jan 02; 287(1):245-256.
    View in: PubMed
    Score: 0.002
  22. Evaluation of 3,3',4'-trihydroxyflavone and 3,6,4'-trihydroxyflavone (4'-O-glucuronidation) as the in vitro functional markers for hepatic UGT1A1. Mol Pharm. 2011 Dec 05; 8(6):2379-89.
    View in: PubMed
    Score: 0.002
  23. First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics. J Pharm Sci. 2011 Sep; 100(9):3655-81.
    View in: PubMed
    Score: 0.002
  24. Development of sulfonamide AKT PH domain inhibitors. Bioorg Med Chem. 2011 Mar 15; 19(6):2046-54.
    View in: PubMed
    Score: 0.002
  25. Three-dimensional quantitative structure-activity relationship studies on UGT1A9-mediated 3-O-glucuronidation of natural flavonols using a pharmacophore-based comparative molecular field analysis model. J Pharmacol Exp Ther. 2011 Feb; 336(2):403-13.
    View in: PubMed
    Score: 0.002
  26. Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor. Mol Cancer Ther. 2010 Mar; 9(3):706-17.
    View in: PubMed
    Score: 0.002
  27. Discovery of a novel class of AKT pleckstrin homology domain inhibitors. Mol Cancer Ther. 2008 Sep; 7(9):2621-32.
    View in: PubMed
    Score: 0.002
  28. Serum response factor micromanaging cardiogenesis. Curr Opin Cell Biol. 2007 Dec; 19(6):618-27.
    View in: PubMed
    Score: 0.001
  29. Neuropathology of thiamine deficiency: an update on the comparative analysis of human disorders and experimental models. Metab Brain Dis. 1996 Mar; 11(1):19-37.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.